Alice Norton

Alice Norton

Auto-generated profile, based on publicly available information

Alice Norton

Oxford Select OX3 7BN Policy and Practice Research Group, Pandemic Sciences Institute, University of Oxford

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2010 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
ANAlice J. Norton
Alice J. Norton
CGCharlotte M. Gower
Charlotte M. Gower
PLPoppy H L Lamberton
Poppy H L Lamberton
BWBonnie L. Webster
Bonnie L. Webster
NLNicholas J. S. Lwambo
Nicholas J. S. Lwambo
JWJoanne P. Webster
Joanne P. Webster
Recent shifts in global health policy have led to the implementation of mass drug administration (MDA) for neglected tropical diseases. Here we show how population genetic analyses can provide vital insights into the impact of such MDA on endemic parasite populations. We show that even a single round of MDA produced a genetic bottleneck with reductions in a range of measures of genetic diversity of Schistosoma mansoni. Phylogenetic analyses and indices of population differentiation indicated that schistosomes collected in the same schools in different years were more dissimilar than those from different schools collected within either of the study's 2 years, in addition to distinguishing re-infection from non-clearance (that might indicate putatively resistant parasites) from within those children infected at both baseline and follow-up. Such unique results illustrate the importance of genetic monitoring and examination of long lived multi-cellular parasites such as these under novel or increased chemotherapeutic selective pressures.

1 November 2013 in Acta Tropica
Verified
Journal Article
Closed access
CGCharlotte M. Gower
Charlotte M. Gower
AGAnouk N. Gouvras
Anouk N. Gouvras
PLPoppy H L Lamberton
Poppy H L Lamberton
ADArminder Deol
Arminder Deol
JSJaya Shrivastava
Jaya Shrivastava
JWJoanne P. Webster
Joanne P. Webster

25 January 2008 in Evolutionary Applications
Verified
Journal Article
Open access
PDF file
JWJoanne P. Webster
Joanne P. Webster
CGCharlotte M. Gower
Charlotte M. Gower
ANAlice J. Norton
Alice J. Norton
Schistosomiasis is a parasitic disease of significant medical and veterinary importance in many regions of the world. Recent shifts in global health policy have led towards the implementation of mass chemotherapeutic control programmes at the national scale in previously 'neglected' countries such as those within sub-Saharan Africa. Evolutionary theory has an important role to play in the design, application and interpretation of such programmes. Whilst celebrating the rapid success achieved to date by such programmes, in terms of reduced infection prevalence, intensity and associated human morbidity, evolutionary change in response to drug selection pressure may be predicted under certain circumstances, particularly in terms of the development of potential drug resistance, evolutionary changes in parasite virulence, transmission and host use, and/or competitive interactions with co-infecting pathogens. Theoretical and empirical data gained to date serve to highlight the importance of careful monitoring and evaluation of parasites and their hosts whenever and wherever chemotherapy is applied and where parasite transmission remains.

29 July 2020 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
ANAlice Norton
Alice Norton
AGArancha De La Horra Gozalo
Arancha De La Horra Gozalo
NCNicole Feune de Colombi
Nicole Feune de Colombi
MAMoses Alobo
Moses Alobo
JAJuliette Mutheu Asego
Juliette Mutheu Asego
TLTrudie Lang
Trudie Lang
Introduction In March 2020, the WHO released a Global Research Roadmap in an effort to coordinate and accelerate the global research response to combat COVID-19 based on deliberations of 400 experts across the world. Three months on, the disease and our understanding have both evolved significantly. As we now tackle a pandemic in very different contexts and with increased knowledge, we sought to build on the work of the WHO to gain a more current and global perspective on these initial priorities. Methods We undertook a mixed methods study seeking the views of the global research community to (1) assess which of the early WHO roadmap priorities are still most pressing; (2) understand whether they are still valid in different settings, regions or countries; and (3) identify any new emerging priorities. Results Thematic analysis of the significant body of combined data shows the WHO roadmap is globally relevant; however, new important priorities have emerged, in particular, pertinent to low and lower middle-income countries (less resourced countries), where health systems are under significant competing pressures. We also found a shift from prioritising vaccine and therapeutic development towards a focus on assessing the effectiveness, risks, benefits and trust in the variety of public health interventions and measures. Our findings also provide insight into temporal nature of these research priorities, highlighting the urgency of research that can only be undertaken within the period of virus transmission, as well as other important research questions but which can be answered outside the transmission period. Both types of studies are key to help combat this pandemic but also importantly to ensure we are better prepared for the future. Conclusion We hope these findings will help guide decision-making across the broad research system including the multilateral partners, research funders, public health practitioners, clinicians and civil society.

1 August 2020 in The Lancet
Verified
Journal Article
Closed access
ANAlice Norton
Alice Norton
JMJeffrey Mphahlele
Jeffrey Mphahlele
YYYazdan Yazdanpanah
Yazdan Yazdanpanah
PPPeter Piot
Peter Piot
MBMarta Tufet Bayona
Marta Tufet Bayona

27 December 2019 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
CFChristina Faust
Christina Faust
MCMarco Crotti
Marco Crotti
AMArinaitwe Moses
Arinaitwe Moses
DODavid Oguttu
David Oguttu
AWAidah Wamboko
Aidah Wamboko
PLPoppy H L Lamberton
Poppy H L Lamberton
Background: A key component of schistosomiasis control is mass drug administration with praziquantel. While control interventions have been successful in several endemic regions, mass drug administration has been less effective in others. Here we focus on the impact of repeated praziquantel treatment on the population structure and genetic diversity of Schistosoma mansoni. Methods: We examined S. mansoni epidemiology, population genetics, and variation in praziquantel susceptibility in parasites isolated from children across three primary schools in a high endemicity region at the onset of the Ugandan National Control Programme. Children were sampled at 11 timepoints over two years, including one week and four weeks post-praziquantel treatment to evaluate short-term impacts on clearance and evidence of natural variation in susceptibility to praziquantel. Results: Prevalence of S. mansoni was 85% at baseline. A total of 3576 miracidia larval parasites, isolated from 203 individual children, were genotyped at seven loci. Overall, genetic diversity was high and there was low genetic differentiation, indicating high rates of parasite gene flow. Schistosome siblings were found both pre-treatment and four weeks post-treatment, demonstrating adult worms surviving treatment and natural praziquantel susceptibility variation in these populations at the beginning of mass drug administration. However, we did not find evidence for selection on these parasites. While genetic diversity decreased in the short-term (four weeks post-treatment), diversity did not decrease over the entire period despite four rounds of mass treatment. Furthermore, within-host genetic diversity was affected by host age, host sex, infection intensity and recent praziquantel treatment. Conclusions: Our findings suggest that praziquantel treatments have short-term impacts on these parasite populations but impacts were transient and no long-term reduction in genetic diversity was observed. High gene flow reduces the likelihood of local adaptation, so even though parasites surviving treatment were observed, these were likely to be diluted at the beginning of the Ugandan National Control Programme. Together, these results suggest that MDA in isolation may be insufficient to reduce schistosome populations in regions with high genetic diversity and gene flow.